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Abstract
Background: The beneficial outcomes of oral anticoagulation therapy are dependent upon achieving and
maintaining an optimal INR therapeutic range. There is growing evidence that better outcomes are achieved when
anticoagulation is managed by a pharmacist with expertise in anticoagulation management rather than usual care
by family physicians. This study compared a pharmacist managed anticoagulation program (PC) to usual physician
care (UC) in a family medicine clinic.
Methods: A retrospective cohort study was carried out in a family medicine clinic which included a clinical
pharmacist. In 2006, the pharmacist assumed anticoagulation management. For a 17-month period, the PC group
(n = 112) of patients on warfarin were compared to the UC patients (n = 81) for a similar period prior to 2006. The
primary outcome was the percentage of time patients’ INR was in the therapeutic range (TTR). Secondary
outcomes were the percentage of time in therapeutic range within ± 0.3 units of the recommended range
(expanded TTR) and percentage of time the INR was >5.0 or <1.5.
Results: The baseline characteristics were similar between the groups. Fifty-five percent of the PC group was male
with a mean age of 67 years; 51% of the UC group was male with a mean age of 71 years. The most common
indications for warfarin in both groups were atrial fibrillation, mechanical heart valves and deep vein thrombosis. The
TTR was 73% for PC and 65% for UC (p < 0.0001). The expanded TTR for PC was 91% and 85% for UC (p < 0.0001).
The percentage of time INR values were <1.5 was 0.7% for PC patients and 1.9% for UC patients (p < 0.0001), and >5
were 0.3% for PC patients and 0.1% for UC (p < 0.0001).
Conclusion: The pharmacist-managed anticoagulation program within a family practice clinic compared to usual
care by the physicians achieved significantly better INR control as measured by the percentage of time patients’
INR values were kept in both the therapeutic and expanded range. Based on the results of this study, a
collaborative family practice clinic using pharmacists and physicians may be an effective model for anticoagulation
management with these results verified in future prospective randomized studies.
Background
Warfarin has been the main oral anticoagulant used for
more than six decades, and its effectiveness for the pre-
vention and treatment of thromboembolism is well estab-
lished [1]. The effectiveness and safety of warfarin is
dependent on maintaining the international normalized
ratio (INR) in a narrow therapeutic range. This is chal-
lenging in clinical practice due to factors including diet
and concurrent medications which may alter the pharma-
cokinetics of warfarin, and therefore the stability of the
INR [2].
Newer oral anticoagulants are available in Canada with
more predictable pharmacologic properties than warfarin
thus eliminating the need for frequent monitoring [3,4].
Ongoing and completed clinical trials with the new
agents will likely expand their usage [5-8]. However,
there may continue to be a need for warfarin, in patient
populations not studied in clinical trials or who are
unable to receive the newer medications due to adverse
effects or contraindications. Consequently, there will be
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an ongoing need for practitioners with an expertise in
anticoagulation management to provide the necessary
level of care to patients still requiring warfarin.
In Canada, patients taking warfarin are usually managed
by their family physician in a clinic setting. The current
recommendation for health care providers managing oral
anticoagulation, is to do so in a “systematic and coordi-
nated fashion, incorporating patient education, systematic
INR testing, tracking, follow-up and good patient commu-
nication” [1]. The complexity of managing oral anticoagu-
lation has led to the development of a variety of specialized
care models including patient self-management, specialized
anticoagulation clinics and pharmacist managed services.
Both observational and randomized controlled trials
have compared anticoagulation management provided by
a pharmacist led anticoagulation clinic versus usual physi-
cian care [9-15]. Some of these studies showed improve-
ment in anticoagulation management by pharmacists
while others have found no difference as measured by the
percentage of time INR was in the therapeutic range
(TTR). Pharmacist-staffed anticoagulation clinic models
point to more consistent monitoring, use of warfarin
dosage adjustment algorithms, early recognition of patient
risk factors, and patient education as the mechanisms by
which they achieve better outcomes than were being
achieved through traditional models of care [9-13]. There
is some evidence to suggest that a pharmacist within a
family practice clinic encourages collaboration with the
physicians, which improves continuity and integration of
care [16]. The current literature does not indicate any
Canadian centres that have examined anticoagulation
management by a pharmacist who was a team member in
a family medicine clinic.
A clinical pharmacist with expertise in anticoagulation
management was incorporated into a family medicine
clinic in St. John’s, NL. As part of this role, the pharmacist
managed the anticoagulation of all clinic patients taking
warfarin using an evidenced-based protocol [1,2,17,18].
We conducted a retrospective cohort study to compare
anticoagulation control by the pharmacist to that provided
by the family physicians.
Methods
Study design and setting
We conducted a retrospective cohort study to compare
the anticoagulation control of pharmacist managed (PC)
oral anticoagulation to usual care (UC) provided by
family physicians. The family medicine clinic is located in
St. John’s, NL, a capital city with a population of approxi-
mately 187 000 [19]. At the time of the study the clinic
was comprised of four to five full-time family physicians
and two part time family physicians, and is affiliated with
Memorial University. The pharmacist joined the clinic in
December 2005 and as part of the position in December
2006 assumed day to day anticoagulation management of
clinic patients receiving warfarin.
Models of Care
Usual Care
The usual care model by the family physicians (prior to
pharmacist management) generally required patients to
have blood drawn by venipuncture for an INR test, and
processed at the local hospital laboratory. The patient was
requested to notify the physician’s office that the test had
been completed. The results were retrieved from the com-
puterized laboratory system by the physician (or clinic staff
and distributed to the physician), most often the same day
as the test was completed. Each individual physician
assessed the result for their patients, and either called their
patient directly via telephone, or had the clinic staff call via
telephone, to inform the patient of the results and changes
if required. Late day results were handled by the clinic on-
call physician. Dosage changes and time intervals for INR
blood tests, as well as warfarin related education were at
the discretion of the individual physician. Depending on
the indication for warfarin, and whether the patient had
been admitted to hospital, they may have received anticoa-
gulation related education prior to presenting to the family
physician for management. No specific dosing nomogram
was utilized; individual physician knowledge and experi-
ence with management of warfarin was utilized. Changes
to warfarin dosing and schedule for next INR were
recorded in the patient’s chart. Most often, the patient’s
usual family physician assessed the results; however, when
their own physician was unavailable, another clinic physi-
cian completed the assessment and management.
Pharmacist Care
The pharmacists involved in the anticoagulation manage-
ment had completed a Bachelor’s degree in Pharmacy, a
Doctor of Pharmacy (Pharm.D.), and two specific, short
(<1 to 6 week) courses in anticoagulation management.
Prior to the pharmacist assuming management of the
warfarin therapy, a clinic-specific protocol was developed
by the pharmacist based on current guidelines and were
approved by the clinic physicians [1,2,17,18]. The format
and content of the protocol followed the recommenda-
tions for delivering optimized anticoagulation therapy in
an outpatient setting [17]. This protocol included evi-
dence-based guidelines regarding dosage recommenda-
tions and intervals for INR testing, but allowed flexibility
for the pharmacist to assess each patient individually to
develop patient-specific recommendations. Similarly to
the physician model, the pharmacist care model required
the patient to have blood drawn for an INR test, usually
by venipuncture and processed at the local hospital
laboratory, and patients were requested notify either the
physician’s office or the pharmacist that the test had
been completed. Patients were managed primarily via
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telephone, with home or clinic visits as needed for initial
education. The pharmacist maintained a list of all the
clinic patients who were receiving warfarin therapy, and
a daily log of patients scheduled for INR testing. The
pharmacist was responsible for retrieving the INR test
results daily (weekdays) from the computerized labora-
tory system, and following up with patients as needed
who did not complete scheduled testing. Late day results
were handled by the pharmacist. Once a test result was
retrieved, the pharmacist telephoned the patient (or care-
giver) and assessed patients for factors that would affect
the result and/or the subsequent recommendation: i.e.,
changes in medications or diet, signs and symptoms of
haemorrhagic or thromboembolic events, missed doses
and illnesses. The pharmacist used the protocol guideline
as well as clinical judgement/specialized knowledge to
develop the care plan of dosage change if required and
follow up INR testing, and provided patient counselling.
Documentation of assessment and recommendations was
made directly into the patient’s chart, and available to the
physicians. The physicians were readily accessible to the
pharmacist for discussion of patient related issues. The
clinic protocol outlined mandatory physician contact by
the pharmacist for discussion of management (i.e.,
INR>5.0, suspicion of serious adverse effects, new clots
or serious bleeding). Patients had the ability to contact
either the physician or the pharmacist for anticoagulation
related questions or concerns.
Data abstraction
A pharmacy student used a data abstraction form to
abstract data from the regional health authority’s compu-
terized database and family physician and pharmacist’s
written and electronic records. Patient demographics, indi-
cations for warfarin, INR target and duration of therapy
and risk factors for bleeding or thromboembolic events
were obtained from the physician (UC group) or pharma-
cist (PC group) records. Results of INR testing, emergency
room visits or inpatient admissions, and verification of
major bleeding and thromboembolic events were obtained
from the regional health authority database. A sample of
completed data collection forms were verified by two
investigators to ensure the validity and reliability of data.
Data were entered into a web based program (ClotFree
System, Genesis Advanced Technologies, Inc, Lakehills,
TX), designed for routine warfarin monitoring and patient
maintenance. Permission was granted to utilize the data-
base for this study using coded patient information.
Eligibility criteria
Patients eligible for inclusion were those ≥ 19 years,
required warfarin for at least 3 months, had at least two
INR values not more than 6 weeks apart and were
patients of the clinic. The INR values used were those
noted in the patients’ records. All eligible patients whose
warfarin was managed by the pharmacist from December
7, 2006 to May 7, 2008 were included in the PC group.
The UC group comprised eligible patients whose war-
farin was managed by a clinic physician between July 6,
2005 up to December 6, 2006. INR values were excluded
from the data if they were within the first 30 days of war-
farin initiation or hospital discharge, during hospitaliza-
tion, or during temporary planned interruptions, which
was considered between the first day warfarin was held
and two weeks after warfarin was restarted [18]. These
are timeframes of potential INR instability, and during
this time they may also be outside the control of either
the pharmacist or the family physician.
Study outcomes
The primary study outcome was to compare anticoagula-
tion control by the pharmacist to that provided by the
family physicians as measured by the percentage of time
patients’ INR was within the recommended therapeutic
range (TTR). The recommended therapeutic range was
either 2.0 to 3.0 or 2.5 to 3.5, as determined by the indica-
tion for anticoagulant therapy [1]. Secondary outcomes
were the percentage of TTR within ± 0.3 units of the
recommended therapeutic range ("expanded therapeutic
range”), percentage of time the INR was above 5.0 or
below 1.5, and number of adverse events i.e., thromboem-
bolic and major haemorrhagic complications [18,20]. As
the time interval between INR tests varies within indivi-
dual patients, as well as the duration of therapy, a standard
measure to indicate frequency of testing over time is num-
ber of INR tests per patient year. The number of INR tests
per patient year in the PC and UC groups was reported.
Guidelines suggest a minimum of four weeks between
INR testing for stable patients [1], with programs often
allowing a maximum time between INR testing of 6 weeks
[15]. For this study, we reported the number of INR tests
greater than 6 weeks apart in the PC and UC groups.
Data analysis and sample size calculation
Based upon prior studies, it was expected that PC oral
anticoagulation would result in at least a 10% absolute
improvement in the percentage TTR as compared to UC
[9,10]. Assuming the standard deviations of the means in
the two groups are equal to 0.25 with an 80% power and a
2-tailed a of 0.05, a sample size of at least 130 patients
was calculated to observe this difference in effect (65 per
group). A p-value of < 0.05 was considered to be statically
significant.
Statistical analysis was performed using Microsoft Excel
2003 (Microsoft Corp., Redmond, WA, USA) and SPSS
statistical software for Windows (version 16.0). Patient
demographics and anticoagulation control were compared
using an unpaired t test, chi-squared tests, or the Fisher
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Exact test, as appropriate. The TTR was calculated by the
ClotFree System using the method described by Rosendaal
and colleagues [21].
Ethics Approval
The Human Investigations Committee at Memorial
University approved the research protocol.
Results
The PC group included 112 patients, of which 73 had
been previously managed in the UC group. The UC
group included 81patients, of which eight had completed
therapy with warfarin prior to the pharmacist assuming
anticoagulation management. Fifty-five percent of the PC
group was male with a mean age of 67 years; 51% of the
UC group was male with a mean age of 71 years. The
most common indications for warfarin in both groups
were atrial fibrillation, mechanical heart valves and deep
vein thrombosis. There was no significant difference in
the demographic characteristics, indications for warfarin,
or risk factors for bleeding or thromboembolic events
between the PC and UC groups (Table 1).
The number of INR tests per patient year in the PC
and UC groups was 29 and 25, respectively. The number
of INR tests per patient-year greater than 6 weeks apart
in the PC and UC groups was 1.3 and 1.8, respectively
(Table 2).
The PC group spent significantly more time in both the
therapeutic range (2.0-3.0 or 2.5-3.5) and the expanded
therapeutic range (i.e., INR range ± 0.3) compared to the
UC group. The percentage of time that the patients INR
was <1.5 was less for the PC group than the UC group.
The percentage of time that the patients INR was >5 was
greater for the PC group than the UC group (Table 3). A
subgroup analysis was conducted on the 73 patients’ com-
mon to both models of care. Similar to the total sample,
the PC group spent significantly more time than the UC
group in the therapeutic range (71.9% vs 65.1%, p <
0.0001), as well as in the expanded therapeutic range
(90.1% vs 85.0%, p < 0.0001).
Two major bleeding events occurred in the PC group
during the study period. One was an abdominal hematoma
in a patient on warfarin for a mechanical heart valve. This
patient had started ciprofloxacin three days prior and had
an INR of 4.04 at the time of the bleed. The second event
was a lower gastrointestinal (GI) bleed in a patient taking
warfarin for atrial fibrillation. The GI bleed was deter-
mined to be due to diverticulosis on sigmoidoscopy. This
patient had an INR of 3.16 at the time of the bleed. In
both cases the bleeds were nonfatal. No major bleeding
events were documented in the UC group during the
study period.
One major thromboembolic event occurred in each of
the PC and UC groups during the study period. The
events occurred in the same patient whose warfarin care
was managed by a physician during the UC timeframe and
managed by the pharmacist during the PC timeframe.
This patient was taking warfarin for atrial fibrillation and
both events were transient ischemic attacks (TIA) requir-
ing emergency room visits. The patient had an INR of
2.11at the time of the TIA while in the UC group and an
INR of 2.44 at the time of the TIA while in the PC group.
Discussion
The results of our study indicate that both models of care
provided high quality anticoagulation management. The
TTR was over 60% for both PC and UC. However, our
results demonstrated that patients in the PC group spent
more time in both the TTR and the expanded TTR
Table 1 Patient Characteristics
Variable Pharmacist
Managed
(PC)
(n = 112)
Physician
Managed
(UC)
(n = 81)
Age in years, mean ± SD 67 ± 18 71 ± 17
Age categories n(%):
≤64 44 (39) 23 (28)
65 to 74 21 (19) 18 (22)
≥75 47 (42) 40 (50)
Sex, male n (%) 62(55) 41 (51)
Indication for anticoagulation, n (%)
Atrial fibrillation 63 (56) 51 (63)
Mechanical heart valve 19(17) 17 (21)
DVT 22(20) 13(16)
PE 16(14) 8(10)
CVA 4 (3) 1 (1)
MI and/or ACS 2(2) 1 (1)
Other 1(1) 0
Target INR range
2.0-3.0 93(83) 65(80)
2.5-3.5 19 (17) 16(20)
Risk Factors for thromboembolism or
bleeding
Hypertension 46(41) 38(47)
Previous CVA 34(30) 26(31)
Previous DVT/PE 26(23) 15 (19)
Diabetes 19(17) 9(11)
Factor II mutation 2(2) 2(3)
Factor V Leiden 7(6) 5(6)
APLS 2(2) 1(1)
ACS - acute coronary syndrome, APLS - antiphospholipid syndrome, CVA -
cerebrovascular accident, DVT - deep vein thrombosis, MI - myocardial
infarction, PE - pulmonary embolism
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compared to the UC group and these differences were
statistically significant. The percentage of time patients’
INR was < 1.5 was lower in the PC group versus the UC
group and the percentage of time patients’ INR was > 5
was higher in the PC group versus UC group. Low num-
bers of adverse clinical events were detected. Our current
study’s findings demonstrate that patients experience bet-
ter anticoagulation control for the TTR and expanded
TTR when managed by a pharmacist with expertise in
anticoagulation management who applies a systematic,
evidenced based approach to patient care.
Several other studies have compared pharmacist man-
aged anticoagulation services to usual care, most often
by a physician. Several of these studies support the cur-
rent study findings while others indicate no difference
[9-15]. The studies that support our findings include
two randomized controlled trials and three observational
studies [9-13]. In one Canadian study, researchers con-
ducted a randomized controlled trial where patients
were allocated to either anticoagulation clinics with a
pharmacist in three tertiary hospitals (n = 112) or to
their family physician practices (n = 109) [9]. Patients
managed by the anticoagulation clinics were within the
expanded therapeutic range more than patients mana-
ged by family physicians (82% vs 76%, p < 0.05). High
risk INR values (<1.5 or >5.0) were more often observed
in patients managed by family physicians (49% vs 39%,
p < 0.05). In another randomized control trial con-
ducted in Hong Kong, patients were randomized to
either a pharmacist managed anticoagulation clinic (n =
68) or physician managed service (n = 69) [10]. Patients
in the pharmacist managed group were within the TTR
more than the physician managed group (64% vs 59%,
p < 0.001). Of the three observational studies, one was
conducted in Canada and two in the United States
[11-13]. In one Canadian prospective cohort study, con-
secutive patients (n = 125) referred to the pharmacist
Anticoagulation Management Service (AMS) with at
least 4 months anticoagulation management prior to
referral were included in a pre- and post-analysis of
anticoagulation control [11]. The anticoagulation control
was greater in the AMS compared with standard care in
the period before referral (66.5% vs 48.8%, p < 0.0001).
Both observational studies conducted in the United
States found pharmacist managed anticoagulation clinics
significantly improved patients anticoagulation control
as measured by the TTR [12,13].
Two studies found no difference in anticoagulation
control between a pharmacist managed anticoagulation
clinic and usual care by a physician [14,15]. In the rando-
mized controlled trial conducted in Quebec, patients sta-
bilized in a pharmacist managed anticoagulation service
(PMAS) in a large community hospital were subsequently
randomly allocated to either continue in the PMAS (n =
128) or be transferred to their physician for follow-up
care (n = 122) [14]. Researchers reported no difference in
patients managed by the PMAS vs physicians in either
the TTR (77.3% vs 76.7%) or expanded TTR (93.0% vs
91.6%). This finding could be explained by a potential
selection bias. Patients spent an average of 11.3 weeks in
the PMAS and were eligible for group allocation only if
they were stable in their anticoagulation control. In addi-
tion, physicians were given the option of agreeing to par-
ticipation for each patient individually or for all their
patients at once. Close to 50% of the participating physi-
cians chose patients on an individual basis to participate
in the study. Consequently this study population may not
have included patients with poorer anticoagulation con-
trol that would likely benefit from a pharmacist managed
program. In the observational cohort study, patients in a
family medicine clinic were cared for either through a
pharmacist managed anticoagulation clinic or in a
Table 2 Frequency of INR testing
Variable Pharmacist
Managed
(PC)
(n = 112)
Physician
Managed
(UC)
(n = 81)
Total number of INR tests 2328 1452
Total patient years 81 59
Number of INR tests per patient year 29 25
INR tests >6weeks apart, n 103 104
Number of INR tests >6 weeks apart per
patient year
1.3 1.8
Table 3 Anticoagulation Control
Variable Pharmacist
Managed (PC)
(n = 112)
Physician
Managed (UC)
(n = 81)
p-value
Percentage of Time INR in Range
Therapeutic range (TTR)* 73.4 64.8 P < 0.0001
Expanded range(Expanded TTR)† 90.8 84.8 P < 0.0001
< 1.5 0.67 1.92 P < 0.0001
>5.0 0.27 0.08 P < 0.0001
*Therapeutic range: 2.0-3.0 or 2.5-3.5; †expanded therapeutic range: therapeutic range ± 0.3
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traditional care model by physicians [15]. Overall, the
authors found no difference in anticoagulation control
between the two groups. However, their method of data
analysis and reporting results were not standard and
make comparisons with other studies difficult.
A prospective randomized control study is generally
considered the gold standard for evaluating therapeutic
interventions. However it may not be the optimal method
to assess this type of intervention as it is difficult to mini-
mize observation biases. As all groups are aware of the
intervention, their behaviours may be influenced accord-
ingly in a prospective randomized trial. For example, phy-
sicians who are aware they are participating in a clinical
trial may be more vigilant about monitoring anticoagula-
tion care than in their routine practice. A well designed
retrospective study may be the next best method. In our
study, all eligible patients were included in the data collec-
tion, and the two groups were comparable, reducing any
selection biases. This study evaluated the anticoagulation
management practices in one family medicine clinic. Our
patient population was similar to that in other studies
evaluating anticoagulation management; consequently, our
findings may be generalizable to other similar populations.
Due to the nature of the retrospective cohort study
design, a number of confounders were not controlled for.
The amount of time spent with patients in each model
was not recorded, neither was the format or content
of education provided. We did observe a subgroup of
patients who crossed over from UC to PC. Although in
subgroup analysis we still found a significant difference in
TTR, we cannot necessarily assume this effect was due to
the pharmacists’ anticoagulation management. We found
significant difference, but more research is needed in this
area. Future research would allow for control of confoun-
ders such as time, education, protocol driven care, multi-
variable regression through prospective randomized
controlled or prospective cohort design.
Conclusions
The pharmacist-managed anticoagulation program within
a family practice clinic compared to usual care by the phy-
sicians achieved significantly better INR control as mea-
sured by the percentage of time patients’ INR values were
kept in both the therapeutic and expanded range. Based
on the results of this study, a collaborative family practice
clinic using pharmacists and physicians may be an effec-
tive structure for an anticoagulation management service
with these results verified in future prospective rando-
mized studies.
Note
Additional information about the specific protocol avail-
able from the corresponding author on request
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